Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02278445
Recruitment Status : Withdrawn (No patients)
First Posted : October 30, 2014
Last Update Posted : December 2, 2015
Sponsor:
Information provided by (Responsible Party):
Echosense Ltd.

Brief Summary:
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel). Systemic sclerosis patients often develop pulmonary vascular disease leading to pulmonary hypertension. The TPD system may provide important insight into pulmonary blood vessels characteristics by the LDS (Lung Doppler Signals) signals that are related to pulmonary hypertension. The TPD performance in detecting PAH in SSc patients will be assessed in the study.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Pulmonary Hypertension Radiation: Doppler ultrasound Device: Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)
Study Start Date : November 2014
Estimated Primary Completion Date : November 2015
Estimated Study Completion Date : December 2015


Arm Intervention/treatment
Experimental: Doppler ultrasound
Recording Doppler ultrasound noninvasively from the right chest wall
Radiation: Doppler ultrasound
Recording Doppler ultrasound noninvasively from the right chest wall

Device: Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)



Primary Outcome Measures :
  1. Number of SSc patients correctly identified with pulmonary hypertension severity in each of the 4 defined groups by RHC. [ Time Frame: 12 month ]
    Analyze Doppler data of 4 SSc groups (according to pulmonary hypertension severity) resulting in typical features. The features will be implemented in a pre-determined diagnostic algorithm that will determine the overall statistical success of the method in comparison to RHC data.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Able and willing to give signed informed consent prior to enrollment
  2. Male or female, ≥ 18 years of age
  3. Diagnosis of SSc according to 2013 ACR/EULAR SSc Classification Criteria (van den Hoogen 2013): Score ≥ 9.
  4. Patients with RHC data available from measurement within 3 weeks prior to TPD assessment
  5. No change in or initiation of PAH specific therapy between the last RHC and TPD

Exclusion Criteria:

  1. People unable or unwilling to give informed consent.
  2. PCWP or LVEDP > 15 mmHg
  3. Any PH etiology outside Group 1 (Dana Point, 2008)
  4. Pregnant women
  5. Patients having severe chest wall deformity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02278445


Locations
Layout table for location information
Israel
Sheba Medical Center, Pulmonology department
Ramat Gan, Israel
Sponsors and Collaborators
Echosense Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Merav Lidar, Dr Sheba medical center, Rheumatology department

Layout table for additonal information
Responsible Party: Echosense Ltd.
ClinicalTrials.gov Identifier: NCT02278445     History of Changes
Other Study ID Numbers: DOP22_3
First Posted: October 30, 2014    Key Record Dates
Last Update Posted: December 2, 2015
Last Verified: August 2014
Keywords provided by Echosense Ltd.:
Systemic Sclerosis
Pulmonary hypertension
Lung Doppler Signals
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension, Pulmonary
Hypertension
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Connective Tissue Diseases
Skin Diseases